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Abstract We have purified a protease with characteristics of 
TNFa convertase from bovine spleen membranes. Peptide 
sequencing of the purified protein identified it as ADAM 10 
(Genbank accession no. Z21961). This metalloprotease cleaves a 
recombinant proTNFa substrate to mature TNFa, and can 
cleave a synthetic peptide substrate to yield the mature TNFa 
amino terminus in vitro. The enzyme is sensitive to a 
hydroxamate inhibitor of MMPs, but insensitive to phosphor-
amidon. In addition, cloned ADAM 10 mediates proTNFa 
processing in a processing-incompetent cell line. 
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1. Introduction 
The pro-inflammatory cytokine TNFa [1-3] is synthesized 
as a 233 amino acid precursor. Conversion of this membrane-
bound precursor to a secreted 17 kDa mature protein [4,5] is 
carried out by an unidentified protease, termed the TN Fa 
convertase. Serine proteases are capable of releasing 
proTNFa from the membrane-bound form, although the re-
sulting amino-terminus is not identical with that observed in 
vivo [6]. Many investigators believe TNFa convertase is a 
membrane-bound metalloprotease [7-9]. This activity is inhib-
ited by EDT A and many prototypic MMP inhibitors but not 
by phosphoramidon, thiorphan, captopril and TIMP-l. This 
activity cleaves the proTNFa at the correct position, yielding 
an amino-terminal valine. We have purified one activity from 
bovine spleen with enzymatic characteristics consistent with 
TNFa convertase. In addition, we show that this protein, 
identified as ADAM 10, can reconstitute TNFa processing 
in a processing-incompetent cell line. 
2. Materials and methods 
2.1. In vitro assay for TNFa convertase activity 
A protein-based assay for TNFa convertase activity was based on 
described procedures [7], using a 125I-labelled peptide-tagged recombi-
nant proTNFa polypeptide substrate (Flag-proTNFa). A membrane 
protein sample was mixed with 2 ng of 125I_polypeptide substrate 
(approx. 50000 cpm) in the presence of inhibitors (0.2 mM PMSF, 
211M pepstatin, 200 11M leupeptin, I mM N-methoxysuccinyl-AAPV-
chloromethyl ketone [AAPVCMK]). Following incubation at 37°C 
overnight, samples were fractionated by SDS-PAGE on a 16% gel. 
Polypeptides were visualized by autoradiography. 
A peptide-based assay for TNFa convertase activity was carried 
out similarly to the procedure described in [7] using an amino-ter-
minal dinitrophenylated peptide substrate (DNP-SPLAQAVRSSSR-
NH2). A membrane protein sample was mixed in 50 III with I Ilg 
peptide substrate in the presence of inhibitors (see above). Following 
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incubation at 37°C, the protein was precipitated by cold 5% trichloro-
acetic acid, 20% acetonitrile and the soluble peptide fraction was 
applied to a YMC 120 A C-18 ODS-AQ column (4.6x 100 mm). 
The column was eluted isocratically at I mllmin using 40% acetonitrile 
plus 0.06% trifiuoroacetic acid. The elution of DNP-peptide was mon-
itored at 360 nm using a Waters 625 LC system. 
2.2. Purification from bovine spleen 
Bovine spleens were purchased from Pel-Freez. The washed tissue 
was homogenized in a Waring blender, resuspended in lysis buffer (20 
mM Tricine, pH 7.8, 8% sucrose) containing 0.1% PMSF, then homo-
genized using a Brinkmann Polytron tissue homogenizer. The cell 
debris was removed by two low-speed centrifugations and the mem-
branes isolated by ultracentrifugation. The isolated membranes were 
washed in 10 mM HEPES, pH 7.5. 
The membrane fraction was resuspended to 8 mglml in buffer A (20 
mM Tris, pH 7.5, I mM MgS04, 10 mM NaC!, 10 11M ZnS04) plus 
2% Brij 35, and incubated at 4°C for 30 min. The membranes were 
collected by ultracentrifugation, then resuspended to 4 mglml in buffer 
A plus 2% Thesit (Boehringer Mannheim). The insoluble protein was 
removed by ultracentrifugation. 
The detergent-solubilized fraction was applied to a chelating Se-
pharose (Pharmacia) column charged with nickel sulfate in buffer A 
with 0.3 M NaCI/O.l% octyl glucoside (all subsequent steps included 
0.1% octyl glucoside). The 50 mM imidazole eluate was concentrated, 
then applied to a Sephacryl 300 (Pharmacia) sieving column equili-
brated in buffer A. A retained fraction (approx. 60 kDa) was pooled, 
then applied to a wheat germ agglutinin column in 0.3 M NaCI and 
eluted with buffer A containing 0.5 M N-acetylglucosamine and 0.5 M 
NaCI. The eluate was dialyzed vs. I mM NaP04 pH 7, then applied to 
an hydroxyapatite (BioRad) column. An eluted fraction (40-50 mM 
NaP04) was then dialyzed vs. buffer A and passed successively over 
HS-20 and HQ-20 (Perseptive Biosystems) ion exchange columns. The 
unbound fraction from both columns contained the TNFa convertase 
activity. 
The final protein fraction (approx. 100 Ilg) was fractionated by 
SDS-PAGE on an 8% gel (Novex), then electrophoretically trans-
ferred to an Imrnobilon filter membrane in 10 mM CAPS buffer, 
pH 10, 10% methanol. After staining the membrane with 0.1% Amido 
Black in 40% methanol, 10% acetic acid, the major protein band was 
excised and used for microsequencing. 
2.3. Cloning and in vivo activity of ADAM 10 
Bovine ADAM 10 (Genbank accession no. Z21961) was cloned 
from 5 Ilg poly(A)+ RNA (Cion tech) using a GibcoBRL SuperScript 
Preamplification System and an oligo(dT) primer. The resulting 
cDNA was used directly for PCR using the listed primers: 
CTTCCGGGTACCCGGAAGATGGTGTTGCTGAGAGTG 
(5' forward) 
CGTTAAAAGCTTTTAACGTCTCATGTGTCCCATCTG 
(3' reverse). 
PCR conditions were: 94°C, 30 s/60°C, 30 s172°C, 2 min for 30 cycles. 
The PCR product was digested with KpnI and HindIII restriction 
enzymes, and was ligated into pCEP4 vector (Invitrogen) 
Human 293EBNA cells (Invitrogen) were seeded into 96-well plates 
at 104 cellsllOO III per well in DMEM containing 10% fetal bovine 
serum, and incubated at 37°C, 5% CO2 for 20 h. Cells were trans-
fected with 50 ng pSRaSPORT/proTNFa vector with or without 100 
ng pCEP4/ADAM 10 using Lipofectin (Gibco-BRL). After 20 h, hu-
man TNFa was detected by ELISA using a human TNFa capture 
antibody (Pharmingen no. 18631D) and a biotinylated anti-TNFa 
(Pharmingen no. 18642D). The bound biotinylated antibody was de-
tected using streptavidin-HRP (BioSource) in concert with ABTS sub-
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Fig. 1. Characterizing the TNFa convertase pool by SDS-polyacryl-
amide gel electrophoresis. TNFa convertase activity was purified 
from bovine spleen as described. Serial dilutions of final preparation 
were fractionated on an 8-16% polyacrylamide gel in SDS. Polypep-
tides were visualized by Coomassie Blue staining. Black arrows de-
note major protein species. 
strate (KP Labs). Visible color development was quantitated at 405 
nm vs. standards. 
3. Results 
After screening several bovine tissues for the ability to 
cleave 125I-Flag-proTNFa to a 17 kDa protein (membrane 
fractions from kidney, spleen and lung contained detectable 
TNFa convertase activity, while heart and liver were inac-
tive), we selected bovine spleen for purification of TNFa con-
vertase. 9 g of bovine spleen membranes were fractionated as 
listed in Section 2. The final pool (Fig. 1) contained two major 
protein bands centered around 60 kDa. Fig. 2 shows the pro-
tein sequences of these bands are consistent with a known 
protein ADAM 10 [10], a metalloprotease with an ill-defined 
biological activity [11,12] (the lower band is a proteolyzed 
product starting at residue 285). ADAM 10 could cleave 
125I-proTNFa to a 17 kDa protein (Fig. 3), and could cleave 
a peptide substrate between Ala and Val, consistent with the 
cleavage site in native TNFa. The peptide-cleaving activity 
was inhibited by EDT A (l mM) and SCH43534, a peptide 
XAEKNTFQl YXQTO DPTNPFRFPNIGVEK VGAPSGSSG 
.... VAEKNTCOl YIOTD ... JI ..... DPTNPFRFPNIGVEK ••• JI ..... VGAPSGSSG .... 
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Fig. 2. Amino acid sequence analysis of the TNFa convertase poly-
peptide. The polypeptides (black arrows in Fig. I) were transferred 
to an Immobilon filter membrane, excised and sequenced. Figure 
shows the alignment of the obtained sequence information with that 
of the known metalloproteinase ADAM 10. 
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Fig. 3. ADAM 10 cleaves a proTNFa substrate. Aliquots of puri-
fied ADAM 10 were mixed with 125I-Flag-proTNFa in a reaction 
containing 0.2 mM PMSF, 2 11M pepstatin, 0.2 mM leupeptin and 
I mM AAPVCMK. Following incubation at 37°C overnight, sam-
ples were fractionated by SDS-PAGE on a 16% gel and radioactiv-
ity detected by autoradiography. Lanes: I, no enzyme control; 2, 
ADAM 10. The upper arrow indicates the uncut proTNFa, about 
21 kDa; the lower arrow denotes the 17 kDa processed TNFa 
band. 
hydroxamate inhibitor of collagenase similar to BB2284 [9], 
but was not inhibited by phosphoramidon (300 flM) and 
thiorphan (100 flM). 
To confirm this result, we sought to determine whether 
cloned bovine ADAM 10 could process pro TN Fa in intact 
cells. Screening numerous cell lines (including CHO, HeLa, 
IEC-6, C2C12 , clone-9) showed that a human embryonic kid-
ney cell line 293EBNA (as well as the parental cell line 293) 
was unable to process recombinant proTNFa, although re-
combinant growth hormone was effectively processed. We 
transfected pSRaSPORTlproTNFa with or without pCEP41 
ADAM 10, then measured TNFa production 20 h later. 
Fig. 4 shows that 293EBNA cannot process recombinant 
proTNFa (sample 1) unless co-transfected with pCEP41 
ADAM 10 (samples 2-5). 
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Fig. 4. ADAM 10 mediates the processing and release of proTNFa 
in vivo. The graph shows the amount of soluble TNFa produced 
with transfection of pSRaSPORT/proTNFa alone (sample 1) and 
after co-transfection with four independent pCEP4/ADAM 10 vec-
tor isolates (samples 2-5). 
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4. Discussion 
We have purified an enzyme capable of proteolytic ally proc-
essing a recombinant proTNFa to native TNFa from bovine 
spleen. A homologous protein was recently purified from hu-
man Monomac 6 cells (data not shown). The protein was 
identified as ADAM 10 [10], a protein first purified from 
bovine brain based on its ability to cleave MBP [11,12]. The 
protein has since been found in many tissues, and is homol-
ogous to the Drosophila kuz protein, suggesting a role in neu-
rogenesis [13]. We show that this protein can cleave proTNFa 
in vitro and in cultured human cells. This result, coupled with 
the numerous other proteolytic activities present in bovine 
tissue that conform to the inhibitor profile and cleavage site 
specificity established for TNFa convertase (data not shown) 
suggests that in vitro activity alone is not sufficient to estab-
lish a protease as TNFa convertase. 
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